 Prem Subramanian
Concepts (438)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Papilledema | 16 | 2023 | 40 | 6.740 |
Why?
| | Optic Disk | 17 | 2023 | 38 | 6.100 |
Why?
| | Optic Nerve Diseases | 15 | 2023 | 31 | 4.540 |
Why?
| | Intracranial Hypertension | 8 | 2023 | 37 | 4.210 |
Why?
| | Optic Neuropathy, Ischemic | 10 | 2023 | 30 | 4.130 |
Why?
| | Pseudotumor Cerebri | 10 | 2023 | 22 | 4.030 |
Why?
| | Tomography, Optical Coherence | 19 | 2023 | 130 | 3.800 |
Why?
| | Visual Fields | 19 | 2022 | 77 | 3.460 |
Why?
| | Vision Disorders | 18 | 2023 | 130 | 3.380 |
Why?
| | Visual Acuity | 18 | 2022 | 274 | 3.060 |
Why?
| | Ophthalmology | 8 | 2024 | 77 | 2.950 |
Why?
| | Optic Neuritis | 8 | 2023 | 37 | 2.470 |
Why?
| | Abducens Nerve Diseases | 5 | 2022 | 10 | 2.460 |
Why?
| | Eye Injuries | 4 | 2021 | 44 | 2.320 |
Why?
| | Hemianopsia | 6 | 2022 | 9 | 2.290 |
Why?
| | Fluorescein Angiography | 10 | 2021 | 102 | 2.190 |
Why?
| | Oculomotor Nerve Diseases | 5 | 2021 | 9 | 2.100 |
Why?
| | Exophthalmos | 4 | 2023 | 19 | 2.050 |
Why?
| | Retinal Ganglion Cells | 10 | 2022 | 92 | 1.920 |
Why?
| | Carotid-Cavernous Sinus Fistula | 4 | 2021 | 7 | 1.900 |
Why?
| | Nerve Fibers | 9 | 2022 | 87 | 1.830 |
Why?
| | Embolization, Therapeutic | 5 | 2021 | 178 | 1.820 |
Why?
| | Eye Diseases, Hereditary | 3 | 2019 | 11 | 1.750 |
Why?
| | Retinal Artery Occlusion | 2 | 2022 | 8 | 1.610 |
Why?
| | Meningioma | 4 | 2023 | 77 | 1.570 |
Why?
| | Diplopia | 6 | 2023 | 16 | 1.540 |
Why?
| | Ocular Motility Disorders | 2 | 2023 | 25 | 1.440 |
Why?
| | Intraocular Pressure | 9 | 2022 | 276 | 1.420 |
Why?
| | Humans | 124 | 2024 | 114623 | 1.340 |
Why?
| | Isaacs Syndrome | 2 | 2023 | 4 | 1.330 |
Why?
| | Graves Ophthalmopathy | 3 | 2023 | 14 | 1.300 |
Why?
| | Astronauts | 4 | 2023 | 18 | 1.280 |
Why?
| | Eye Diseases | 4 | 2021 | 76 | 1.260 |
Why?
| | Orbit | 6 | 2023 | 59 | 1.250 |
Why?
| | Perceptual Disorders | 2 | 2019 | 20 | 1.230 |
Why?
| | Retina | 5 | 2022 | 263 | 1.200 |
Why?
| | Optic Nerve | 6 | 2023 | 65 | 1.160 |
Why?
| | Orbital Diseases | 4 | 2013 | 25 | 1.120 |
Why?
| | Space Flight | 4 | 2023 | 127 | 1.100 |
Why?
| | Optic Disk Drusen | 4 | 2020 | 5 | 1.100 |
Why?
| | Multiple Sclerosis | 3 | 2018 | 376 | 1.090 |
Why?
| | Color Vision Defects | 2 | 2017 | 6 | 1.070 |
Why?
| | Neurology | 4 | 2021 | 84 | 1.050 |
Why?
| | Trochlear Nerve Diseases | 3 | 2023 | 6 | 1.030 |
Why?
| | Orbital Neoplasms | 2 | 2018 | 21 | 0.980 |
Why?
| | Ophthalmic Artery | 3 | 2021 | 6 | 0.980 |
Why?
| | Academies and Institutes | 2 | 2024 | 44 | 0.960 |
Why?
| | Eye | 3 | 2021 | 98 | 0.920 |
Why?
| | Glaucoma | 6 | 2023 | 202 | 0.920 |
Why?
| | Stroke | 3 | 2017 | 1021 | 0.880 |
Why?
| | Visual Field Tests | 9 | 2020 | 13 | 0.850 |
Why?
| | Magnetic Resonance Imaging | 12 | 2023 | 3039 | 0.840 |
Why?
| | Intracranial Aneurysm | 2 | 2022 | 91 | 0.830 |
Why?
| | Ophthalmologic Surgical Procedures | 4 | 2018 | 57 | 0.830 |
Why?
| | Orbital Pseudotumor | 2 | 2018 | 3 | 0.830 |
Why?
| | Intracranial Pressure | 5 | 2023 | 48 | 0.800 |
Why?
| | Absorption, Physiological | 1 | 2021 | 4 | 0.800 |
Why?
| | Embolism | 1 | 2022 | 43 | 0.790 |
Why?
| | Prostaglandins, Synthetic | 1 | 2021 | 6 | 0.790 |
Why?
| | Myofibroma | 1 | 2021 | 4 | 0.790 |
Why?
| | Neuromyelitis Optica | 1 | 2023 | 115 | 0.780 |
Why?
| | Adie Syndrome | 1 | 2021 | 1 | 0.770 |
Why?
| | Cerebral Small Vessel Diseases | 1 | 2021 | 1 | 0.770 |
Why?
| | Cerebrospinal Fluid | 1 | 2021 | 90 | 0.760 |
Why?
| | Societies, Medical | 2 | 2024 | 663 | 0.750 |
Why?
| | Nasal Mucosa | 1 | 2021 | 93 | 0.750 |
Why?
| | Meningeal Neoplasms | 3 | 2023 | 87 | 0.750 |
Why?
| | Adult | 37 | 2023 | 30528 | 0.740 |
Why?
| | Weapons | 1 | 2021 | 9 | 0.740 |
Why?
| | Civil Disorders | 1 | 2021 | 8 | 0.740 |
Why?
| | Recreation | 1 | 2021 | 21 | 0.740 |
Why?
| | Political Activism | 1 | 2021 | 10 | 0.730 |
Why?
| | Male | 50 | 2022 | 55554 | 0.730 |
Why?
| | Hallucinations | 1 | 2020 | 30 | 0.720 |
Why?
| | Virtual Reality | 1 | 2021 | 38 | 0.720 |
Why?
| | Middle Aged | 39 | 2021 | 26719 | 0.710 |
Why?
| | Arteriovenous Malformations | 2 | 2011 | 24 | 0.700 |
Why?
| | Glaucoma, Open-Angle | 2 | 2020 | 95 | 0.700 |
Why?
| | Peripheral Nerves | 2 | 2020 | 64 | 0.690 |
Why?
| | Choroid | 1 | 2020 | 47 | 0.680 |
Why?
| | Macula Lutea | 2 | 2019 | 15 | 0.670 |
Why?
| | Regional Blood Flow | 1 | 2021 | 424 | 0.660 |
Why?
| | Cerebrovascular Circulation | 1 | 2021 | 221 | 0.650 |
Why?
| | Vertigo | 1 | 2019 | 37 | 0.640 |
Why?
| | Demyelinating Diseases | 1 | 2019 | 75 | 0.640 |
Why?
| | Optic Nerve Neoplasms | 3 | 2023 | 12 | 0.630 |
Why?
| | Optic Chiasm | 5 | 2021 | 18 | 0.630 |
Why?
| | Female | 47 | 2022 | 59466 | 0.620 |
Why?
| | Optic Atrophy, Hereditary, Leber | 3 | 2023 | 4 | 0.620 |
Why?
| | Sinus Thrombosis, Intracranial | 2 | 2020 | 21 | 0.610 |
Why?
| | Sphenoid Sinus | 1 | 2017 | 8 | 0.600 |
Why?
| | Paranasal Sinus Diseases | 1 | 2017 | 14 | 0.590 |
Why?
| | Reimbursement Mechanisms | 1 | 2018 | 77 | 0.580 |
Why?
| | Cranial Sinuses | 2 | 2014 | 12 | 0.570 |
Why?
| | Contrast Sensitivity | 2 | 2015 | 12 | 0.560 |
Why?
| | Giant Cell Arteritis | 4 | 2022 | 48 | 0.560 |
Why?
| | Postural Balance | 1 | 2019 | 183 | 0.540 |
Why?
| | Aged | 22 | 2022 | 19061 | 0.540 |
Why?
| | Visual Pathways | 2 | 2013 | 44 | 0.530 |
Why?
| | Retinopathy of Prematurity | 3 | 2023 | 111 | 0.530 |
Why?
| | Diagnostic Techniques, Ophthalmological | 3 | 2021 | 36 | 0.510 |
Why?
| | Head and Neck Neoplasms | 1 | 2020 | 427 | 0.510 |
Why?
| | Arteriovenous Fistula | 2 | 2006 | 29 | 0.510 |
Why?
| | Color Perception Tests | 1 | 2015 | 3 | 0.510 |
Why?
| | Color Vision | 1 | 2015 | 2 | 0.510 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 2015 | 28 | 0.500 |
Why?
| | Carotid Artery, Internal | 3 | 2021 | 36 | 0.490 |
Why?
| | Recovery of Function | 2 | 2017 | 574 | 0.490 |
Why?
| | Nervous System Diseases | 3 | 2020 | 253 | 0.490 |
Why?
| | Therapy, Computer-Assisted | 1 | 2015 | 58 | 0.490 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 577 | 0.480 |
Why?
| | Cerebrovascular Disorders | 2 | 2013 | 82 | 0.470 |
Why?
| | Blindness | 2 | 2015 | 37 | 0.470 |
Why?
| | Aspergillosis | 2 | 2013 | 23 | 0.470 |
Why?
| | Young Adult | 17 | 2020 | 10455 | 0.460 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 2014 | 31 | 0.460 |
Why?
| | Brain Injuries, Traumatic | 1 | 2018 | 301 | 0.450 |
Why?
| | Headache | 5 | 2021 | 132 | 0.450 |
Why?
| | Circle of Willis | 1 | 2013 | 6 | 0.440 |
Why?
| | Endarterectomy, Carotid | 1 | 2013 | 42 | 0.440 |
Why?
| | Medical Audit | 1 | 2013 | 75 | 0.440 |
Why?
| | Decompression, Surgical | 1 | 2014 | 93 | 0.440 |
Why?
| | Referral and Consultation | 1 | 2018 | 632 | 0.430 |
Why?
| | Retrospective Studies | 18 | 2023 | 12542 | 0.430 |
Why?
| | Ischemic Attack, Transient | 1 | 2013 | 62 | 0.420 |
Why?
| | Medicare | 1 | 2018 | 665 | 0.420 |
Why?
| | Skin Neoplasms | 1 | 2020 | 756 | 0.420 |
Why?
| | Ophthalmologists | 2 | 2024 | 12 | 0.410 |
Why?
| | Cerebral Angiography | 4 | 2021 | 109 | 0.410 |
Why?
| | Lymphangioma | 1 | 2011 | 7 | 0.390 |
Why?
| | Varicose Veins | 1 | 2011 | 14 | 0.390 |
Why?
| | Diagnosis, Differential | 4 | 2023 | 1342 | 0.380 |
Why?
| | Eye Infections, Fungal | 1 | 2010 | 6 | 0.370 |
Why?
| | Oculomotor Muscles | 2 | 2023 | 40 | 0.370 |
Why?
| | Aspergillus fumigatus | 1 | 2010 | 20 | 0.360 |
Why?
| | Algorithms | 6 | 2023 | 1466 | 0.360 |
Why?
| | Follow-Up Studies | 7 | 2021 | 4411 | 0.360 |
Why?
| | Brain Diseases | 1 | 2011 | 124 | 0.350 |
Why?
| | Cross-Sectional Studies | 7 | 2023 | 4405 | 0.350 |
Why?
| | ROC Curve | 6 | 2021 | 442 | 0.350 |
Why?
| | United States | 10 | 2024 | 12176 | 0.330 |
Why?
| | Practice Patterns, Physicians' | 2 | 2018 | 1177 | 0.330 |
Why?
| | Military Medicine | 2 | 2008 | 93 | 0.320 |
Why?
| | Postoperative Complications | 3 | 2013 | 2128 | 0.320 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 900 | 0.320 |
Why?
| | Retinal Vein | 1 | 2008 | 13 | 0.320 |
Why?
| | Cerebrospinal Fluid Proteins | 1 | 2008 | 10 | 0.310 |
Why?
| | Strabismus | 1 | 2008 | 26 | 0.310 |
Why?
| | Brain | 3 | 2021 | 2371 | 0.290 |
Why?
| | Eye Movements | 2 | 2018 | 53 | 0.290 |
Why?
| | Corneal Edema | 1 | 2007 | 3 | 0.290 |
Why?
| | Iraq War, 2003-2011 | 1 | 2008 | 151 | 0.290 |
Why?
| | Eye Pain | 2 | 2017 | 7 | 0.290 |
Why?
| | Ophthalmoplegia, Chronic Progressive External | 1 | 2007 | 3 | 0.290 |
Why?
| | Mitochondrial Myopathies | 1 | 2007 | 4 | 0.290 |
Why?
| | Prostatectomy | 1 | 2007 | 98 | 0.290 |
Why?
| | Astigmatism | 2 | 2006 | 10 | 0.280 |
Why?
| | Photorefractive Keratectomy | 2 | 2006 | 13 | 0.280 |
Why?
| | Stents | 3 | 2016 | 475 | 0.280 |
Why?
| | Septo-Optic Dysplasia | 1 | 2006 | 4 | 0.270 |
Why?
| | Craniocerebral Trauma | 1 | 2008 | 134 | 0.270 |
Why?
| | Temporal Arteries | 3 | 2022 | 47 | 0.270 |
Why?
| | Visual Cortex | 1 | 2006 | 41 | 0.270 |
Why?
| | Prospective Studies | 9 | 2019 | 6217 | 0.270 |
Why?
| | Cavernous Sinus | 2 | 2021 | 14 | 0.260 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2008 | 219 | 0.260 |
Why?
| | Ophthalmoscopy | 3 | 2021 | 30 | 0.250 |
Why?
| | Carotid Artery Diseases | 1 | 2005 | 57 | 0.250 |
Why?
| | Transverse Sinuses | 2 | 2016 | 8 | 0.250 |
Why?
| | Ocular Hypertension | 3 | 2015 | 61 | 0.250 |
Why?
| | Adolescent | 11 | 2021 | 17831 | 0.240 |
Why?
| | Retinal Artery | 1 | 2004 | 15 | 0.240 |
Why?
| | Retinitis | 1 | 2004 | 17 | 0.240 |
Why?
| | Retinal Vasculitis | 1 | 2004 | 7 | 0.240 |
Why?
| | Peptide Hormones | 1 | 2004 | 8 | 0.240 |
Why?
| | Aneurysm | 1 | 2004 | 29 | 0.230 |
Why?
| | Ultrasonography | 2 | 2021 | 633 | 0.220 |
Why?
| | Laser Coagulation | 2 | 2019 | 54 | 0.220 |
Why?
| | Physicians | 2 | 2022 | 772 | 0.220 |
Why?
| | Eyeglasses | 1 | 2003 | 4 | 0.220 |
Why?
| | Diphosphonates | 1 | 2003 | 51 | 0.220 |
Why?
| | Parvovirinae | 1 | 2022 | 1 | 0.210 |
Why?
| | Eye Burns | 1 | 2022 | 11 | 0.210 |
Why?
| | Radiation Injuries | 1 | 2004 | 128 | 0.210 |
Why?
| | Paralysis | 1 | 2023 | 66 | 0.210 |
Why?
| | Myopia | 1 | 2003 | 36 | 0.210 |
Why?
| | Arteries | 2 | 2021 | 247 | 0.210 |
Why?
| | Compartment Syndromes | 1 | 2022 | 30 | 0.210 |
Why?
| | Eyelid Diseases | 1 | 2022 | 21 | 0.210 |
Why?
| | Cornea | 1 | 2003 | 102 | 0.200 |
Why?
| | Blood Pressure | 1 | 2008 | 1538 | 0.200 |
Why?
| | Fluorometry | 1 | 2021 | 19 | 0.200 |
Why?
| | Oculomotor Nerve | 1 | 2021 | 5 | 0.200 |
Why?
| | Fundus Oculi | 2 | 2020 | 40 | 0.200 |
Why?
| | Endovascular Procedures | 2 | 2018 | 269 | 0.200 |
Why?
| | Aged, 80 and over | 5 | 2017 | 6344 | 0.200 |
Why?
| | Dinoprost | 1 | 2021 | 31 | 0.200 |
Why?
| | Administration, Intranasal | 1 | 2021 | 75 | 0.190 |
Why?
| | Skull Base | 1 | 2021 | 39 | 0.190 |
Why?
| | Retinal Vessels | 1 | 2021 | 50 | 0.190 |
Why?
| | Bone Neoplasms | 1 | 2003 | 194 | 0.190 |
Why?
| | Posture | 2 | 2019 | 152 | 0.190 |
Why?
| | Dissent and Disputes | 1 | 2021 | 18 | 0.190 |
Why?
| | Ubiquinone | 1 | 2020 | 21 | 0.180 |
Why?
| | Lewy Bodies | 1 | 2020 | 7 | 0.180 |
Why?
| | Wounds and Injuries | 1 | 2008 | 745 | 0.180 |
Why?
| | Crowding | 1 | 2021 | 37 | 0.180 |
Why?
| | Treatment Outcome | 8 | 2020 | 9084 | 0.180 |
Why?
| | Antigens, Viral | 1 | 2021 | 176 | 0.180 |
Why?
| | Vision, Ocular | 1 | 2020 | 30 | 0.180 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 92 | 0.180 |
Why?
| | Prostatic Neoplasms | 2 | 2007 | 921 | 0.180 |
Why?
| | Macular Degeneration | 1 | 2022 | 152 | 0.180 |
Why?
| | Fluorescent Dyes | 1 | 2021 | 301 | 0.170 |
Why?
| | Fovea Centralis | 1 | 2019 | 8 | 0.170 |
Why?
| | Risk Factors | 6 | 2023 | 8628 | 0.170 |
Why?
| | Congresses as Topic | 1 | 2021 | 195 | 0.170 |
Why?
| | Neurosurgical Procedures | 2 | 2018 | 152 | 0.170 |
Why?
| | Sensitivity and Specificity | 4 | 2022 | 1691 | 0.170 |
Why?
| | DNA, Viral | 1 | 2021 | 350 | 0.170 |
Why?
| | Microvessels | 1 | 2020 | 68 | 0.170 |
Why?
| | Inflammation | 4 | 2023 | 2477 | 0.160 |
Why?
| | Quality of Life | 4 | 2022 | 2353 | 0.160 |
Why?
| | Health Surveys | 1 | 2021 | 443 | 0.160 |
Why?
| | Retinal Detachment | 1 | 2019 | 53 | 0.160 |
Why?
| | Dizziness | 1 | 2019 | 70 | 0.160 |
Why?
| | Ligation | 1 | 2018 | 75 | 0.160 |
Why?
| | Tonometry, Ocular | 3 | 2019 | 83 | 0.160 |
Why?
| | Skull Base Neoplasms | 1 | 2018 | 24 | 0.150 |
Why?
| | Child | 7 | 2022 | 18404 | 0.150 |
Why?
| | Forms and Records Control | 1 | 2018 | 22 | 0.150 |
Why?
| | Periodicals as Topic | 1 | 2020 | 181 | 0.150 |
Why?
| | Healthy Volunteers | 1 | 2019 | 197 | 0.150 |
Why?
| | Disease Progression | 3 | 2020 | 2380 | 0.150 |
Why?
| | Transcranial Direct Current Stimulation | 1 | 2017 | 4 | 0.150 |
Why?
| | Social Media | 1 | 2020 | 131 | 0.150 |
Why?
| | Capillaries | 1 | 2018 | 91 | 0.150 |
Why?
| | Angiogenesis Inhibitors | 1 | 2019 | 214 | 0.150 |
Why?
| | Herpesvirus 3, Human | 1 | 2021 | 378 | 0.150 |
Why?
| | Headache Disorders | 1 | 2017 | 12 | 0.150 |
Why?
| | Betacoronavirus | 1 | 2020 | 250 | 0.140 |
Why?
| | Prevalence | 2 | 2016 | 2249 | 0.140 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 1 | 1997 | 24 | 0.140 |
Why?
| | X Chromosome | 1 | 1997 | 47 | 0.140 |
Why?
| | Accidents, Traffic | 1 | 2018 | 170 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2022 | 322 | 0.140 |
Why?
| | Infant | 5 | 2023 | 7959 | 0.140 |
Why?
| | Machine Learning | 1 | 2020 | 316 | 0.140 |
Why?
| | Arteritis | 1 | 2016 | 27 | 0.140 |
Why?
| | Area Under Curve | 2 | 2014 | 274 | 0.140 |
Why?
| | Education, Medical, Graduate | 1 | 2020 | 368 | 0.140 |
Why?
| | Neuronal Plasticity | 2 | 2017 | 209 | 0.130 |
Why?
| | Activities of Daily Living | 1 | 2019 | 349 | 0.130 |
Why?
| | Constriction, Pathologic | 2 | 2014 | 208 | 0.130 |
Why?
| | Abducens Nerve | 1 | 2015 | 3 | 0.130 |
Why?
| | Animals | 5 | 2021 | 31694 | 0.130 |
Why?
| | Pandemics | 2 | 2022 | 1317 | 0.130 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2020 | 682 | 0.130 |
Why?
| | Autoantibodies | 1 | 2023 | 1345 | 0.130 |
Why?
| | DNA Replication | 1 | 1997 | 202 | 0.130 |
Why?
| | Melanoma | 1 | 2021 | 619 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 338 | 0.120 |
Why?
| | Recurrence | 1 | 2018 | 935 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 330 | 0.120 |
Why?
| | Lateral Sinus Thrombosis | 1 | 2015 | 1 | 0.120 |
Why?
| | Myocardial Ischemia | 1 | 2016 | 235 | 0.120 |
Why?
| | Telemedicine | 1 | 2023 | 662 | 0.120 |
Why?
| | Health Policy | 1 | 2018 | 334 | 0.120 |
Why?
| | Case-Control Studies | 2 | 2016 | 3003 | 0.120 |
Why?
| | Gestational Age | 3 | 2023 | 759 | 0.120 |
Why?
| | Syndrome | 3 | 2019 | 333 | 0.110 |
Why?
| | Incidence | 3 | 2022 | 2311 | 0.110 |
Why?
| | Carbamazepine | 1 | 2013 | 18 | 0.110 |
Why?
| | Practice Guidelines as Topic | 1 | 2021 | 1394 | 0.110 |
Why?
| | Cognition | 1 | 2020 | 988 | 0.110 |
Why?
| | Reproducibility of Results | 2 | 2018 | 2762 | 0.110 |
Why?
| | Abscess | 1 | 2013 | 72 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 1879 | 0.100 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 4689 | 0.100 |
Why?
| | Carotid Artery, Internal, Dissection | 1 | 2012 | 6 | 0.100 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 510 | 0.100 |
Why?
| | Obesity | 1 | 2004 | 2507 | 0.100 |
Why?
| | Hemodynamics | 1 | 2016 | 1012 | 0.100 |
Why?
| | Predictive Value of Tests | 2 | 2014 | 1796 | 0.100 |
Why?
| | Vision, Binocular | 1 | 2011 | 15 | 0.100 |
Why?
| | Anticonvulsants | 1 | 2013 | 179 | 0.100 |
Why?
| | DNA Transposable Elements | 1 | 1992 | 101 | 0.090 |
Why?
| | Artificial Intelligence | 2 | 2023 | 144 | 0.090 |
Why?
| | Genetic Therapy | 2 | 2023 | 257 | 0.090 |
Why?
| | Neonatal Screening | 2 | 2023 | 152 | 0.090 |
Why?
| | Penicillin G Benzathine | 1 | 2010 | 1 | 0.090 |
Why?
| | Syphilis Serodiagnosis | 1 | 2010 | 3 | 0.090 |
Why?
| | Penicillin G | 1 | 2010 | 7 | 0.090 |
Why?
| | Psychology | 1 | 2011 | 81 | 0.090 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1121 | 0.090 |
Why?
| | Histoplasmosis | 1 | 2010 | 14 | 0.090 |
Why?
| | Military Personnel | 2 | 2008 | 523 | 0.090 |
Why?
| | Time Factors | 5 | 2020 | 6112 | 0.090 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2010 | 112 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 1992 | 993 | 0.080 |
Why?
| | Venous Pressure | 1 | 2008 | 8 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2023 | 663 | 0.080 |
Why?
| | Birth Weight | 2 | 2023 | 440 | 0.080 |
Why?
| | Disease Models, Animal | 1 | 2017 | 3531 | 0.080 |
Why?
| | Escherichia coli | 1 | 1992 | 720 | 0.080 |
Why?
| | Iraq | 1 | 2008 | 81 | 0.080 |
Why?
| | Cohort Studies | 2 | 2016 | 4894 | 0.080 |
Why?
| | Afghanistan | 1 | 2008 | 108 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2010 | 951 | 0.070 |
Why?
| | Infant, Newborn | 3 | 2023 | 5043 | 0.070 |
Why?
| | Lasers, Excimer | 2 | 2006 | 21 | 0.070 |
Why?
| | Darkness | 1 | 2006 | 23 | 0.070 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2006 | 16 | 0.070 |
Why?
| | Mice | 1 | 2021 | 14860 | 0.060 |
Why?
| | Functional Laterality | 1 | 2006 | 198 | 0.060 |
Why?
| | Prognosis | 1 | 2013 | 3328 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2013 | 979 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2013 | 2279 | 0.060 |
Why?
| | Maxillary Artery | 1 | 2005 | 3 | 0.060 |
Why?
| | Growth Cones | 1 | 2004 | 6 | 0.060 |
Why?
| | Angiography, Digital Subtraction | 1 | 2005 | 44 | 0.060 |
Why?
| | Bucladesine | 1 | 2004 | 24 | 0.060 |
Why?
| | Platinum | 1 | 2005 | 38 | 0.060 |
Why?
| | Retinal Hemorrhage | 1 | 2004 | 18 | 0.060 |
Why?
| | Ganglia, Spinal | 1 | 2004 | 41 | 0.060 |
Why?
| | Veins | 1 | 2005 | 55 | 0.060 |
Why?
| | Body Constitution | 1 | 2004 | 47 | 0.060 |
Why?
| | Ghrelin | 1 | 2004 | 33 | 0.060 |
Why?
| | Nerve Regeneration | 1 | 2004 | 50 | 0.060 |
Why?
| | Stereotaxic Techniques | 1 | 2004 | 29 | 0.060 |
Why?
| | Growth Hormone | 1 | 2004 | 103 | 0.060 |
Why?
| | Psychomotor Performance | 1 | 2006 | 280 | 0.060 |
Why?
| | Tubulin | 1 | 2004 | 123 | 0.060 |
Why?
| | Demography | 1 | 2024 | 260 | 0.050 |
Why?
| | Leptin | 1 | 2004 | 210 | 0.050 |
Why?
| | Equipment Design | 1 | 2005 | 508 | 0.050 |
Why?
| | Magnetic Resonance Angiography | 1 | 2005 | 219 | 0.050 |
Why?
| | Angiography | 1 | 2023 | 174 | 0.050 |
Why?
| | Prednisone | 1 | 2003 | 229 | 0.050 |
Why?
| | Baltimore | 2 | 2012 | 43 | 0.050 |
Why?
| | DNA, Mitochondrial | 1 | 2023 | 182 | 0.050 |
Why?
| | Methylprednisolone | 1 | 2022 | 81 | 0.050 |
Why?
| | Paraffin Embedding | 1 | 2021 | 21 | 0.050 |
Why?
| | Tissue Fixation | 1 | 2021 | 27 | 0.050 |
Why?
| | Formaldehyde | 1 | 2021 | 46 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2023 | 329 | 0.050 |
Why?
| | Spinal Cord Injuries | 1 | 2004 | 174 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2022 | 289 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2021 | 76 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2010 | 1477 | 0.050 |
Why?
| | Safety | 1 | 2003 | 297 | 0.050 |
Why?
| | Firearms | 1 | 2006 | 297 | 0.050 |
Why?
| | Myasthenia Gravis | 1 | 2020 | 18 | 0.040 |
Why?
| | Light | 1 | 2003 | 336 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2021 | 139 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 4620 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2003 | 447 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2021 | 193 | 0.040 |
Why?
| | Axial Length, Eye | 1 | 2019 | 9 | 0.040 |
Why?
| | Tertiary Prevention | 1 | 2019 | 3 | 0.040 |
Why?
| | Immunomodulation | 1 | 2020 | 84 | 0.040 |
Why?
| | Weight Loss | 1 | 2004 | 641 | 0.040 |
Why?
| | Intravitreal Injections | 1 | 2019 | 45 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 1660 | 0.040 |
Why?
| | Extraterrestrial Environment | 1 | 2019 | 11 | 0.040 |
Why?
| | Academic Medical Centers | 2 | 2012 | 410 | 0.040 |
Why?
| | India | 1 | 2019 | 134 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 385 | 0.040 |
Why?
| | Centrifugation | 1 | 2018 | 31 | 0.040 |
Why?
| | Gravity, Altered | 1 | 2018 | 9 | 0.040 |
Why?
| | Child, Preschool | 1 | 2012 | 9108 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2023 | 785 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2019 | 222 | 0.040 |
Why?
| | Blood Loss, Surgical | 1 | 2018 | 84 | 0.040 |
Why?
| | Primary Prevention | 1 | 2019 | 172 | 0.040 |
Why?
| | Rotation | 1 | 2018 | 110 | 0.040 |
Why?
| | Acetazolamide | 1 | 2017 | 30 | 0.040 |
Why?
| | Hybrid Cells | 1 | 1997 | 49 | 0.040 |
Why?
| | Diuretics | 1 | 2017 | 66 | 0.040 |
Why?
| | Antioxidants | 1 | 2020 | 530 | 0.030 |
Why?
| | Body Mass Index | 1 | 2004 | 1956 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 1997 | 133 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2019 | 498 | 0.030 |
Why?
| | Cricetinae | 1 | 1997 | 253 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 646 | 0.030 |
Why?
| | Weight Reduction Programs | 1 | 2017 | 94 | 0.030 |
Why?
| | Analgesics | 1 | 2017 | 158 | 0.030 |
Why?
| | Cloning, Molecular | 1 | 1997 | 522 | 0.030 |
Why?
| | Azacitidine | 1 | 1997 | 129 | 0.030 |
Why?
| | Infant, Premature | 1 | 2019 | 476 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2017 | 271 | 0.030 |
Why?
| | Sex Distribution | 1 | 2016 | 337 | 0.030 |
Why?
| | Treatment Failure | 1 | 2016 | 331 | 0.030 |
Why?
| | Vision Tests | 1 | 2015 | 15 | 0.030 |
Why?
| | Enzyme Activation | 1 | 1997 | 785 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1518 | 0.030 |
Why?
| | Insulin | 1 | 2004 | 2076 | 0.030 |
Why?
| | Heart Rate | 1 | 2018 | 709 | 0.030 |
Why?
| | Vaccination | 1 | 2022 | 1204 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2014 | 109 | 0.030 |
Why?
| | Itraconazole | 1 | 2013 | 7 | 0.030 |
Why?
| | Tinnitus | 1 | 2015 | 58 | 0.030 |
Why?
| | Immunocompetence | 1 | 2013 | 40 | 0.030 |
Why?
| | Chromatin | 1 | 1997 | 428 | 0.030 |
Why?
| | Voriconazole | 1 | 2013 | 24 | 0.030 |
Why?
| | Debridement | 1 | 2013 | 73 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2004 | 2319 | 0.030 |
Why?
| | Comorbidity | 1 | 2017 | 1448 | 0.030 |
Why?
| | Disease Management | 1 | 2016 | 560 | 0.030 |
Why?
| | Antifungal Agents | 1 | 2013 | 128 | 0.030 |
Why?
| | Mutation | 1 | 2023 | 3344 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 2013 | 90 | 0.030 |
Why?
| | Triazoles | 1 | 2013 | 131 | 0.030 |
Why?
| | DNA Probes | 1 | 1992 | 59 | 0.020 |
Why?
| | Mutagenesis, Insertional | 1 | 1992 | 61 | 0.020 |
Why?
| | Neurosurgery | 1 | 2012 | 26 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1992 | 167 | 0.020 |
Why?
| | Diabetes Complications | 1 | 2013 | 211 | 0.020 |
Why?
| | Neuroimaging | 1 | 2013 | 249 | 0.020 |
Why?
| | History, 20th Century | 1 | 2012 | 264 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 1992 | 487 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 1992 | 372 | 0.020 |
Why?
| | Acute Disease | 1 | 2013 | 910 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 1992 | 311 | 0.020 |
Why?
| | Pyrimidines | 1 | 2013 | 376 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1629 | 0.020 |
Why?
| | Base Sequence | 1 | 1992 | 2114 | 0.020 |
Why?
| | Coronary Artery Disease | 1 | 2013 | 607 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 1992 | 2785 | 0.020 |
Why?
| | Postoperative Period | 1 | 2006 | 289 | 0.020 |
Why?
| | Hypertension | 1 | 2013 | 1056 | 0.020 |
Why?
| | Visual Perception | 1 | 2006 | 139 | 0.020 |
Why?
| | Tissue Transplantation | 1 | 2004 | 11 | 0.020 |
Why?
| | Axonal Transport | 1 | 2004 | 21 | 0.010 |
Why?
| | Growth Inhibitors | 1 | 2004 | 43 | 0.010 |
Why?
| | Up-Regulation | 1 | 2004 | 807 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2218 | 0.010 |
Why?
| | Rats | 1 | 2004 | 4958 | 0.010 |
Why?
|
|
Subramanian's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|